Last reviewed 2026-04-23 · How we verify

KX-826-（5%） BID

KX-826 is a topical androgen receptor antagonist that inhibits DHT-mediated signaling in hair follicles to treat androgenetic alopecia.

KX-826 is a topical androgen receptor antagonist that inhibits DHT-mediated signaling in hair follicles to treat androgenetic alopecia. Used for Androgenetic alopecia (male pattern baldness).

At a glance

Mechanism of action

KX-826 works by blocking the androgen receptor in dermal papilla cells and other hair follicle structures, preventing dihydrotestosterone (DHT) from triggering hair loss. By locally antagonizing androgen signaling without systemic absorption, it aims to halt hair miniaturization and promote hair growth while minimizing systemic side effects associated with oral antiandrogens.

Approved indications

• Androgenetic alopecia (male pattern baldness)

Common side effects

• Scalp irritation
• Erythema
• Pruritus

Key clinical trials

• To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia (PHASE2)
• Phase III Study of KX-826 With Adult Male Patients With AGA (PHASE3)
• Phase II Study Evaluating the Efficacy and Safety of KX-826 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• KX-826-（5%） BID CI brief — competitive landscape report
• KX-826-（5%） BID updates RSS · CI watch RSS
• Suzhou Kintor Pharmaceutical Inc, portfolio CI